Effects of amiodarone and its active metabolite desethylamiodarone on the ventricular defibrillation threshold. (Q52241572)

27 April 2018

title

Effects of amiodarone and its active metabolite desethylamiodarone on the ventricular defibrillation threshold. (English)

1 reference

27 April 2018

1 reference

Zhou L

1

1 reference

27 April 2018

Chen BP

2

1 reference

27 April 2018

Kluger J

3

1 reference

27 April 2018

Fan C

4

1 reference

27 April 2018

Chow MS

5

1 reference

27 April 2018

language of work or name

English

0 references

publication date

1 June 1998

1 reference

27 April 2018

Journal of the American College of Cardiology

published in

1 reference

27 April 2018

volume

31

1 reference

27 April 2018

issue

7

1 reference

27 April 2018

page(s)

1672-1678

1 reference

27 April 2018

Long-term outcome with the automatic implantable cardioverter-defibrillator.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900160-0

7 January 2021

Randomized study of implantable defibrillator as first-choice therapy versus conventional strategy in postinfarct sudden death survivors

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900160-0

7 January 2021

Long-term results of amiodarone therapy in patients with recurrent sustained ventricular tachycardia or ventricular fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900160-0

7 January 2021

Reduction in sudden death and total mortality by antiarrhythmic therapy evaluated by electrophysiologic drug testing: criteria of efficacy in patients with sustained ventricular tachyarrhythmia

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900160-0

7 January 2021

Evaluation of antiarrhythmic drugs on defibrillation energy requirements in dogs. Sodium channel block and action potential prolongation

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900160-0

7 January 2021

Lidocaine causes a reversible, concentration-dependent increase in defibrillation energy requirements.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900160-0

7 January 2021

Drug-device interactions: clinical considerations

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900160-0

7 January 2021

Amiodarone-induced refractoriness to cardioversion

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900160-0

7 January 2021

The implanted defibrillator: relation of defibrillating lead configuration and clinical variables to defibrillation threshold

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900160-0

7 January 2021

Effect of amiodarone on ventricular fibrillation and defibrillation thresholds in the canine heart under normal and ischemic conditions

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900160-0

7 January 2021

Effects of acute intravenous and chronic oral amiodarone on defibrillation energy requirements

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900160-0

7 January 2021

The effect of chronic oral and acute intravenous amiodarone administration on ventricular defibrillation threshold using implanted electrodes in dogs

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900160-0

7 January 2021

Relation between amiodarone and desethylamiodarone plasma concentrations and ventricular defibrillation energy requirements

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900160-0

7 January 2021

A comparison of the electrophysiologic effects of intravenous and oral amiodarone in the same patient

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900160-0

7 January 2021

Acute and chronic effects of amiodarone on ventricular refractoriness, intraventricular conduction and ventricular tachycardia induction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900160-0

7 January 2021

Effect of amiodarone on conduction and refractoriness of the His-Purkinje system in the human heart

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900160-0

7 January 2021

QT prolongation and the antiarrhythmic efficacy of amiodarone

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900160-0

7 January 2021

Pharmacodynamics of Intravenous Amiodarone in the Dog

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900160-0

7 January 2021

Electrophysiologic effects of amiodarone: experimental and clinical observation relative to serum and tissue drug concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900160-0

7 January 2021

Comparative electrophysiologic effects of intravenous amiodarone and desethylamiodarone in dogs: evidence for clinically relevant activity of the metabolite

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900160-0

7 January 2021

Analysis of amiodarone and desethylamiodarone in serum and tears by reversed-phase high-performance liquid chromatography

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900160-0

7 January 2021

Pharmacology and pharmacokinetics of amiodarone

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900160-0

7 January 2021

The historical development, cellular electrophysiology and pharmacology of amiodarone

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900160-0

7 January 2021

Effects of chronic amiodarone therapy on defibrillation threshold

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900160-0

7 January 2021

Acute effects of intravenous propafenone on the internal ventricular defibrillation threshold in the anesthetized dog

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900160-0

7 January 2021

Effect of recainam on the energy required for ventricular defibrillation in dogs as assessed with implanted electrodes

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900160-0

7 January 2021

Effects of amiodarone and its metabolite, desethylamiodarone, on the electrophysiologic properties of isolated cardiac muscle

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900160-0

7 January 2021

Block of inactivated sodium channels and of depolarization-induced automaticity in guinea pig papillary muscle by amiodarone

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900160-0

7 January 2021

Use-dependent effects of amiodarone on Vmax in cardiac Purkinje and ventricular muscle fibers

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900160-0

7 January 2021

Oral clofilium produces sustained lowering of defibrillation energy requirements in a canine model

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900160-0

7 January 2021

Mechanism of antiarrhythmic drug-induced changes in defibrillation threshold: role of potassium and sodium channel conductance.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900160-0

7 January 2021

Adrenergically mediated variations in the energy required to defibrillate the heart: observations in closed-chest, nonanesthetized dogs

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900160-0

7 January 2021

Effects of lidocaine and verapamil on defibrillation in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900160-0

7 January 2021

Differential effects of lidocaine on defibrillation threshold with monophasic versus biphasic shock waveforms.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900160-0

7 January 2021

Patients with a high defibrillation threshold: clinical characteristics, management, and outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900160-0

7 January 2021

10.1016/S0735-1097(98)00160-0

Identifiers

DOI

1 reference

27 April 2018

1 reference

27 April 2018